Abstract
The maintenance of pancreatic β-cells normal functioning is crucial for insulin production and glucose homeostasis. Inadequate insulin secretion due to β-cell dysfunction can lead to different types of diabetes mellitus. Though it is widely recognized that both environmental and genetic factors play important roles, the exact molecular mechanism that leads to β -cell failure is still unclear. MicroRNAs (miRNAs) regulate numerous physiological and pathophysiological processes at the epigenetic level. miRNAs have been reported to participate in the process of pancreatic development and insulin biosynthesis. Some miRNAs may control insulin secretion and exocytosis through regulating ATP/ADP ratio. In this review, we will summarize the pathological roles of miRNAs in β-cell dysfunction and briefly discuss miRNAs as possible biomarkers and potential pharmaceutical target for diabetes mellitus.
Graphical Abstract
Current Signal Transduction Therapy
Title:MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Volume: 9 Issue: 2
Author(s): Yaxi Chen, Haoming Tian and Xijie Yu
Affiliation:
Keywords: Biomarker, β cells, diabetes, insulin, miRNAs.
Abstract: The maintenance of pancreatic β-cells normal functioning is crucial for insulin production and glucose homeostasis. Inadequate insulin secretion due to β-cell dysfunction can lead to different types of diabetes mellitus. Though it is widely recognized that both environmental and genetic factors play important roles, the exact molecular mechanism that leads to β -cell failure is still unclear. MicroRNAs (miRNAs) regulate numerous physiological and pathophysiological processes at the epigenetic level. miRNAs have been reported to participate in the process of pancreatic development and insulin biosynthesis. Some miRNAs may control insulin secretion and exocytosis through regulating ATP/ADP ratio. In this review, we will summarize the pathological roles of miRNAs in β-cell dysfunction and briefly discuss miRNAs as possible biomarkers and potential pharmaceutical target for diabetes mellitus.
Export Options
About this article
Cite this article as:
Chen Yaxi, Tian Haoming and Yu Xijie, MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362410666150114230309
DOI https://dx.doi.org/10.2174/1574362410666150114230309 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ
Current Vascular Pharmacology Age Related Macular Degeneration and Visual Disability
Current Drug Targets Understanding The Role of Inflammasome in Angina Pectoris
Current Protein & Peptide Science Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model
Current Bioactive Compounds Use of microRNAs as Anti-Atherosclerosis
Mini-Reviews in Medicinal Chemistry Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Reducing the Risk of Type 2 Diabetes - Early Identification of High-Risk Individuals and Treatment with Acarbose
Current Diabetes Reviews Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Bone Metabolism and Histomorphometric Changes in Murine Models Treated with Sclerostin Antibody: A Systematic Review
Current Drug Targets The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets SIRT1 as a Therapeutic Target in Diabetic Complications
Current Medicinal Chemistry Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Context-Dependent Regulation of Nrf2/ARE Axis on Vascular Cell Function during Hyperglycemic Condition
Current Diabetes Reviews Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Current Protein & Peptide Science Mechanisms of Platelet Activation in Acute Coronary Syndromes
Current Vascular Pharmacology